SEMAGLUTIDE

Brand name:

• Wegovy®

Pharmaceutical company:

NOVO NORDISK PHARMACEUTICALS PTY. LIMITED

Condition/indication:
(therapeutic use)

• Established cardiovascular disease (eCVD) with obesity

PBAC Submission type:

New PBS listing (–)

Comment:

--

Public Summary Document:

Not yet available

Related medicines:

• SEMAGLUTIDE

Submission received for:

November 2025 PBAC meeting

Opportunity for consumer comment:

Open 30/07/2025 and close 24/09/2025 (see PBS Website)

PBAC meeting:

Held on 05/11/2025

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

20/02/2026

5Lodgement of required documentation:

6Agreement to listing arrangements:

Has not yet commenced

7Government processes:

Has not yet commenced

8Medicine listed on the PBS:

Has not yet occurred

---